Skip to main content
Clinical Trials/CTRI/2024/07/069896
CTRI/2024/07/069896
Not yet recruiting
Phase 2

A Clinical Trial to Evaluate The Efficacy Of Kasmaryadi Kwatha In The Management Of Hyperuricemia. - NI

I0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease
Sponsor
I
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
I

Eligibility Criteria

Inclusion Criteria

  • 1\) Subjects in the age group between 18\-60 years having elevated Serum uric acid
  • level above 6\.8 mg/dL.
  • 2\) Subjects irrespective of gender and socio\-economic status.
  • 3\) Subjects who are willing to sign the consent form.

Exclusion Criteria

  • 1\) Pregnant and lactating women.
  • 2\) Subjects with known cases of Malignancy, Diabetes mellitus, any Concurrent
  • Hepatic disorders, Chronic Renal failure, Hyperthyroidism and Hypothyroidism
  • 3\) Subjects on medication with aspirin (low dose 1\-2 g per day), beta blockers and
  • alpha \-1 blockers for hypertension, antidepressants, modern diuretics and on
  • medication of hyperuricemia.
  • 4\) Known alcoholic subjects and subjects consuming high purine diet.

Outcomes

Primary Outcomes

Not specified

Similar Trials